BiotechTube

Sunitinib Malate (SU011248)

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Liposarcoma

Conditions

Liposarcoma, Leiomyosarcoma, Fibrosarcoma, Malignant Fibrous Histiocytoma

Trial Timeline

Nov 1, 2006 → Dec 1, 2011

NCT ID
NCT00400569

About Sunitinib Malate (SU011248)

Sunitinib Malate (SU011248) is a phase 2 stage product being developed by Pfizer for Liposarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00400569. Target conditions include Liposarcoma, Leiomyosarcoma, Fibrosarcoma.

What happened to similar drugs?

0 of 1 similar drugs in Liposarcoma were approved

Approved (0) Terminated (0) Active (1)
🔄Abemaciclib + PlaceboEli LillyPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT00793871ApprovedCompleted
NCT00706706ApprovedCompleted
NCT00400569Phase 2Completed
NCT00457743Phase 1/2Completed

Competing Products

12 competing products in Liposarcoma

See all competitors
ProductCompanyStageHype Score
Abemaciclib + PlaceboEli LillyPhase 3
44
efatutazoneDaiichi SankyoPhase 2
35
Eribulin MesylateEisaiPhase 1
33
Trabectedin + DexamethasoneJohnson & JohnsonPhase 2
35
Yondelis + Yondelis + Dexamethasone + DexamethasoneJohnson & JohnsonPhase 2
35
HDM201 + LEE011NovartisPhase 1
29
pazopanibNovartisPhase 2
35
PF-07220060 + MidazolamPfizerPhase 2
39
CabazitaxelSanofiPhase 2
35
INCMGA00012 + PalbociclibIncytePhase 2
36
Selinexor + PlaceboKaryopharm TherapeuticsPhase 2/3
28
Selinexor + IxazomibKaryopharm TherapeuticsPhase 1
11